Off-label promotions and kickback claims can lead to civil and criminal investigations and lawsuits for life sciences companies. With the U.S. Department of Justice's ongoing interest in combating fraud, employers should prioritize minimizing exposure to qui tam allegations and whistle-blower retaliation claims.
